UNSPSC 51433703: Tasosartan

This classification denotes an angiotensin ii type 1 receptor blocker with the molecular formula C23H21N7O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48G92V856H, chemically known as 5,8-dihydro-2,4-dimethyl-8-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)pyrido(2,3-d)pyrimidin-7(6h)-one but generally known as tasosartan, which bears US NIH Compound Identifier 60919. European Medicines Agency schedules Tasosartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10834MIG.

UNSPSC 51433703 Tasosartan is a Commodity code that reflects state and local procurement of prescription medications and pharmaceutical products for emergency medical services, public health programs, and cooperative purchasing arrangements. State and local governments solicit under this code primarily to stock medications for fire rescue departments, health benefit programs, and multi-jurisdictional pharmacy networks. Issuing bodies include municipal fire departments (represented by the City of Tampa), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local members (Minnesota Multistate Cooperative Purchasing Alliance). The work being procured ranges from small-volume sealed-bid purchases of emergency medications with strict expiration and delivery requirements, to exploratory requests for information on direct-to-manufacturer prescription fulfillment models, to large multi-state pharmaceutical framework agreements for generic drugs and OTC products distributed through authorized wholesalers.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) with a due date of April 8, 2026 and estimated contract value of $40,000.00, requiring delivery within ten calendar days and nine-month minimum shelf life. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, with no award values disclosed at the RFI stage. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with contract terms effective July 1, 2026 and performance penalties ranging from $200 to $1,500 per violation. MMCAP requires vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act standards.